Human immunodeficiency virus-associated malignancies: A therapeutic update

Antonello Malfitano, Giuseppe Barbaro, Alessandro Perretti, Giorgio Barbarini

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Implementation of highly active antiretroviral therapy (HAART) has deeply changed the landscape of HIV-associated malignancies. Some AIDS-defining tumors, namely Primitive Lymphoma of Central Nervous System, have drastically declined, whereas a steady increase has been observed for non-AIDS-defining tumors, maybe due to longer survival of HIV-infected people. Easier immune restoration, subsequent to availability of a number of drugs targeting HIV at different points, has decreased opportunistic infections which hampered treatment of HIV-associated cancers. As a matter of fact these patients have been assimilated more and more with their negative counterpart, undergoing the same aggressive approach. Consistently, procedures that have been so far precluded to HIV + subjects, such as transplant of hemopoietic stem cells, either autologous or allogenic, and liver transplant are expected to be performed more and more extensively in this population. Which also would mean a full removal of the stigma which has weighed on it. Hence, it is true-like that malignancies and related problems may in the next future make up a main concern for the HIV specialist. Old and new challenges might be the drug-drug interaction of antiretrovirals or biotherapy-related infections or the debated question of an earlier HAART implementation in the course of HIV disease, with CD4 + cells >500/μl. In fact, if assimilation of HIV patients with cancer and the general population is a remarkable achieved goal, uniqueness of HIV infection in terms of immune status still makes HIV-associated cancer a unique chapter in the setting of Oncology.

Original languageEnglish
Pages (from-to)123-132
Number of pages10
JournalCurrent HIV Research
Volume10
Issue number2
DOIs
Publication statusPublished - Mar 2012

Fingerprint

HIV
Neoplasms
Therapeutics
Highly Active Antiretroviral Therapy
Transplants
Biological Therapy
Second Primary Neoplasms
Opportunistic Infections
Drug Delivery Systems
Secondary Prevention
Drug Interactions
Population
HIV Infections
Lymphoma
Acquired Immunodeficiency Syndrome
Stem Cells
Central Nervous System
Survival
Liver
Infection

Keywords

  • Biotherapy
  • Chemotherapy
  • Highly active antiretroviral therapy
  • Human immunodeficiency virus
  • Malignancies
  • Stem cell rescue

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Human immunodeficiency virus-associated malignancies : A therapeutic update. / Malfitano, Antonello; Barbaro, Giuseppe; Perretti, Alessandro; Barbarini, Giorgio.

In: Current HIV Research, Vol. 10, No. 2, 03.2012, p. 123-132.

Research output: Contribution to journalArticle

@article{589406d82e5e4201b7cd49fb9af44ae8,
title = "Human immunodeficiency virus-associated malignancies: A therapeutic update",
abstract = "Implementation of highly active antiretroviral therapy (HAART) has deeply changed the landscape of HIV-associated malignancies. Some AIDS-defining tumors, namely Primitive Lymphoma of Central Nervous System, have drastically declined, whereas a steady increase has been observed for non-AIDS-defining tumors, maybe due to longer survival of HIV-infected people. Easier immune restoration, subsequent to availability of a number of drugs targeting HIV at different points, has decreased opportunistic infections which hampered treatment of HIV-associated cancers. As a matter of fact these patients have been assimilated more and more with their negative counterpart, undergoing the same aggressive approach. Consistently, procedures that have been so far precluded to HIV + subjects, such as transplant of hemopoietic stem cells, either autologous or allogenic, and liver transplant are expected to be performed more and more extensively in this population. Which also would mean a full removal of the stigma which has weighed on it. Hence, it is true-like that malignancies and related problems may in the next future make up a main concern for the HIV specialist. Old and new challenges might be the drug-drug interaction of antiretrovirals or biotherapy-related infections or the debated question of an earlier HAART implementation in the course of HIV disease, with CD4 + cells >500/μl. In fact, if assimilation of HIV patients with cancer and the general population is a remarkable achieved goal, uniqueness of HIV infection in terms of immune status still makes HIV-associated cancer a unique chapter in the setting of Oncology.",
keywords = "Biotherapy, Chemotherapy, Highly active antiretroviral therapy, Human immunodeficiency virus, Malignancies, Stem cell rescue",
author = "Antonello Malfitano and Giuseppe Barbaro and Alessandro Perretti and Giorgio Barbarini",
year = "2012",
month = "3",
doi = "10.2174/157016212799937227",
language = "English",
volume = "10",
pages = "123--132",
journal = "Current HIV Research",
issn = "1570-162X",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Human immunodeficiency virus-associated malignancies

T2 - A therapeutic update

AU - Malfitano, Antonello

AU - Barbaro, Giuseppe

AU - Perretti, Alessandro

AU - Barbarini, Giorgio

PY - 2012/3

Y1 - 2012/3

N2 - Implementation of highly active antiretroviral therapy (HAART) has deeply changed the landscape of HIV-associated malignancies. Some AIDS-defining tumors, namely Primitive Lymphoma of Central Nervous System, have drastically declined, whereas a steady increase has been observed for non-AIDS-defining tumors, maybe due to longer survival of HIV-infected people. Easier immune restoration, subsequent to availability of a number of drugs targeting HIV at different points, has decreased opportunistic infections which hampered treatment of HIV-associated cancers. As a matter of fact these patients have been assimilated more and more with their negative counterpart, undergoing the same aggressive approach. Consistently, procedures that have been so far precluded to HIV + subjects, such as transplant of hemopoietic stem cells, either autologous or allogenic, and liver transplant are expected to be performed more and more extensively in this population. Which also would mean a full removal of the stigma which has weighed on it. Hence, it is true-like that malignancies and related problems may in the next future make up a main concern for the HIV specialist. Old and new challenges might be the drug-drug interaction of antiretrovirals or biotherapy-related infections or the debated question of an earlier HAART implementation in the course of HIV disease, with CD4 + cells >500/μl. In fact, if assimilation of HIV patients with cancer and the general population is a remarkable achieved goal, uniqueness of HIV infection in terms of immune status still makes HIV-associated cancer a unique chapter in the setting of Oncology.

AB - Implementation of highly active antiretroviral therapy (HAART) has deeply changed the landscape of HIV-associated malignancies. Some AIDS-defining tumors, namely Primitive Lymphoma of Central Nervous System, have drastically declined, whereas a steady increase has been observed for non-AIDS-defining tumors, maybe due to longer survival of HIV-infected people. Easier immune restoration, subsequent to availability of a number of drugs targeting HIV at different points, has decreased opportunistic infections which hampered treatment of HIV-associated cancers. As a matter of fact these patients have been assimilated more and more with their negative counterpart, undergoing the same aggressive approach. Consistently, procedures that have been so far precluded to HIV + subjects, such as transplant of hemopoietic stem cells, either autologous or allogenic, and liver transplant are expected to be performed more and more extensively in this population. Which also would mean a full removal of the stigma which has weighed on it. Hence, it is true-like that malignancies and related problems may in the next future make up a main concern for the HIV specialist. Old and new challenges might be the drug-drug interaction of antiretrovirals or biotherapy-related infections or the debated question of an earlier HAART implementation in the course of HIV disease, with CD4 + cells >500/μl. In fact, if assimilation of HIV patients with cancer and the general population is a remarkable achieved goal, uniqueness of HIV infection in terms of immune status still makes HIV-associated cancer a unique chapter in the setting of Oncology.

KW - Biotherapy

KW - Chemotherapy

KW - Highly active antiretroviral therapy

KW - Human immunodeficiency virus

KW - Malignancies

KW - Stem cell rescue

UR - http://www.scopus.com/inward/record.url?scp=84860308004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860308004&partnerID=8YFLogxK

U2 - 10.2174/157016212799937227

DO - 10.2174/157016212799937227

M3 - Article

C2 - 22329518

AN - SCOPUS:84860308004

VL - 10

SP - 123

EP - 132

JO - Current HIV Research

JF - Current HIV Research

SN - 1570-162X

IS - 2

ER -